Potomac, MD, United States of America

Alfred D Steinberg

This inventor holds 15 USPTO granted patents and 3 EPO patents, primarily in Immunotherapy Research. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc.. Active years: 2001-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alfred D Steinberg. Retrieved from https://idiyas.com/inventor/alfred-d-steinberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 13.3


Average Co-Inventor Count = 3.3

ph-index = 13

Forward Citations = 1,067(Granted Patents)


Company Filing History:


Years Active: 2001-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Immunomodulatory Oligonucleotides
Immunostimulatory Nucleic Acids
Cancer Treatment
Infectious Disease
Nucleic Acid Molecules
Immunotherapy
Therapeutic Applications
Cancer Immunotherapy
Disease Prevention
Biotechnology
Molecular Medicine
Nucleotide Sequences
15 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Alfred D. Steinberg

Introduction

Alfred D. Steinberg is a prominent inventor based in Potomac, MD, known for his significant contributions to the field of immunology. With a total of 15 patents to his name, Steinberg has made remarkable advancements in therapeutic methods aimed at stimulating immune responses.

Latest Patents

Among his latest patents, Steinberg has developed immunomodulatory oligonucleotides that contain unmethylated CpG dinucleotides. These oligonucleotides have therapeutic utilities based on their ability to stimulate an immune response in subjects. His work also includes therapies for treating diseases associated with immune system activation, which are initiated by unmethylated CpG dinucleotides. These therapies involve administering oligonucleotides that do not contain unmethylated CpG sequences to outcompete unmethylated CpG nucleic acids for binding. Additionally, he has disclosed methylated CpG containing dinucleotides for use in antisense therapies or as in vivo hybridization probes, as well as immunoinhibitory oligonucleotides for use as antiviral therapeutics. Furthermore, his research on immunostimulatory nucleic acid molecules highlights their ability to redirect a Th2 response to a Th1 response, providing methods for treating atopic diseases, including atopic dermatitis.

Career Highlights

Steinberg has had a distinguished career, working with esteemed organizations such as the University of Iowa Research Foundation and the National Institutes of Health, a component of the US Department of Health & Human Services. His work has significantly impacted the understanding and treatment of immune-related conditions.

Collaborations

Throughout his career, Steinberg has collaborated with notable individuals in the field, including Arthur Mertz Krieg and Dennis M. Klinman. These collaborations have further enriched his research and contributions to immunology.

Conclusion

Alfred D. Steinberg's innovative work in immunology and his numerous patents underscore his vital role in advancing therapeutic strategies for immune system-related diseases. His contributions continue to influence the field and pave the way for future research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…